Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) shares were up 3.9% during trading on Wednesday . The stock traded as high as $10.85 and last traded at $10.85. Approximately 1,889 shares traded hands during trading, a decline of 54% from the average daily volume of 4,100 shares. The stock had previously closed at $10.44.
Clinuvel Pharmaceuticals Price Performance
The firm has a 50-day moving average of $10.03 and a 200-day moving average of $11.60.
Clinuvel Pharmaceuticals Increases Dividend
The company also recently announced a dividend, which was paid on Monday, October 2nd. Investors of record on Friday, September 8th were given a $0.0283 dividend. This is an increase from Clinuvel Pharmaceuticals’s previous dividend of $0.02. The ex-dividend date was Thursday, September 7th.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
See Also
- Five stocks we like better than Clinuvel Pharmaceuticals
- How to Invest in Cannabis, Step by Step
- 3 value stocks you shouldn’t let go of this quarter
- The Significance of Brokerage Rankings in Stock Selection
- 5 must-have next-gen technologies that institutions are buying
- Stock Sentiment Analysis: How it Works
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
